Highview Capital Management LLC DE raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 4.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,133 shares of the company’s stock after purchasing an additional 217 shares during the period. Highview Capital Management LLC DE’s holdings in AbbVie were worth $1,014,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. FCG Investment Co bought a new stake in shares of AbbVie in the 1st quarter worth approximately $1,413,000. BluePath Capital Management LLC lifted its stake in AbbVie by 0.9% in the first quarter. BluePath Capital Management LLC now owns 7,311 shares of the company’s stock valued at $1,331,000 after buying an additional 67 shares during the last quarter. Palisade Asset Management LLC grew its position in shares of AbbVie by 65.6% during the first quarter. Palisade Asset Management LLC now owns 97,341 shares of the company’s stock worth $17,726,000 after acquiring an additional 38,562 shares during the last quarter. First Hawaiian Bank increased its holdings in shares of AbbVie by 9.0% in the 2nd quarter. First Hawaiian Bank now owns 32,099 shares of the company’s stock worth $5,506,000 after acquiring an additional 2,657 shares during the period. Finally, PGGM Investments lifted its position in AbbVie by 308.1% in the 2nd quarter. PGGM Investments now owns 32,790 shares of the company’s stock valued at $5,624,000 after purchasing an additional 24,756 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at AbbVie
In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.00. Following the completion of the transaction, the chairman now owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.25% of the stock is currently owned by insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on ABBV
AbbVie Trading Down 0.1 %
Shares of NYSE ABBV opened at $189.50 on Wednesday. The business has a fifty day simple moving average of $193.75 and a 200-day simple moving average of $178.75. The company has a market cap of $334.63 billion, a price-to-earnings ratio of 56.23, a P/E/G ratio of 2.66 and a beta of 0.63. AbbVie Inc. has a 12 month low of $135.85 and a 12 month high of $199.95. The company has a quick ratio of 0.71, a current ratio of 0.81 and a debt-to-equity ratio of 8.51.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of 3.27%. The ex-dividend date of this dividend is Tuesday, October 15th. AbbVie’s payout ratio is 183.98%.
AbbVie Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also
- Five stocks we like better than AbbVie
- How to Start Investing in Real Estate
- Financial Stocks Holding Firm Near Highs: 2 Key Players to Watch
- The 3 Best Fintech Stocks to Buy Now
- Upwork Fortifies Profitability Plan With Raised Q3 Forecasts
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 2 Small Modular Reactor Stocks Racing to Power AI Data Centers
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.